Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S. Gottlieb AB, et al. Among authors: gerdes s. J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27696577 Free PMC article.
Adipokines and psoriasis.
Gerdes S, Rostami-Yazdi M, Mrowietz U. Gerdes S, et al. Exp Dermatol. 2011 Feb;20(2):81-7. doi: 10.1111/j.1600-0625.2010.01210.x. Exp Dermatol. 2011. PMID: 21255085 Review.
Psoriasis: to treat or to manage?
Mrowietz U, Steinz K, Gerdes S. Mrowietz U, et al. Among authors: gerdes s. Exp Dermatol. 2014 Oct;23(10):705-9. doi: 10.1111/exd.12437. Epub 2014 Aug 2. Exp Dermatol. 2014. PMID: 24815425 Review.
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Griffiths CEM, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J; EGALITY study group; Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M. Griffiths CEM, et al. Among authors: gerdes s. Br J Dermatol. 2017 Apr;176(4):928-938. doi: 10.1111/bjd.15152. Epub 2017 Mar 1. Br J Dermatol. 2017. PMID: 27787890 Clinical Trial.
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S, Thaçi D, Griffiths CEM, Arenberger P, Poetzl J, Wuerth G, Afonso M, Woehling H. Gerdes S, et al. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-427. doi: 10.1111/jdv.14605. Epub 2017 Nov 2. J Eur Acad Dermatol Venereol. 2018. PMID: 28960486 Free PMC article. Clinical Trial.
231 results